Struggling to Conceive? Your Genes May Hold the Answer.

MTHFR is the enzyme that converts dietary folate into methylfolate, the active form your cells actually use. This isn’t a minor detail. Methylation is the on-and-off switch for gene expression in your developing embryo. It controls whether genes needed for proper neural tube development, cell division, and organ formation get turned on at the right time.

The MTHFR C677T variant, carried by roughly 40% of people with European ancestry, reduces this enzyme’s efficiency by 40 to 70%. That means your cells are converting folate into usable methylfolate at a fraction of the rate they should. If you’re trying to conceive or pregnant, this matters acutely. Your embryo needs optimal methylation to develop normally, and suboptimal MTHFR function makes that harder. Your partner’s MTHFR status also matters because sperm DNA methylation patterns affect embryo development.

You might be eating plenty of leafy greens and taking standard prenatal vitamins. But if you have an MTHFR variant, regular folate isn’t being converted efficiently. Your homocysteine levels may be creeping up, a marker of poor methylation that’s associated with miscarriage risk and pregnancy complications. You’re functionally folate depleted at the cellular level, even if blood work says you’re fine.

FSHR is the receptor on your ovarian cells that listens to FSH, the hormone that triggers egg growth and ovulation. Think of it as the antenna on your eggs. FSH is the radio signal. If your antenna isn’t tuned right, the signal comes through garbled. Your ovaries don’t respond as strongly, even if FSH levels are normal.

The N680S variant, present in roughly 10 to 15% of women, reduces how sensitively your ovaries respond to FSH stimulation. If you have the S/S genotype, your ovaries are simply less responsive to the same FSH dose that works for other women. This matters acutely in IVF cycles. You might need higher stimulation doses, longer stimulation protocols, or still end up with fewer mature eggs than expected despite aggressive protocols.

You go into IVF and your doctor is surprised at your poor ovarian response. Your FSH starts high but your follicles don’t grow as fast. You get fewer eggs. Your cycle is cancelled or you retrieve a smaller cohort. You leave feeling like your body failed. Your body didn’t fail. Your ovaries are simply wired to be less responsive to FSH. Different protocols work better for you.

ESR1 codes for the estrogen receptor in your endometrium, the lining of your uterus. Estrogen doesn’t just cause growth and thickening. It programs your endometrium to accept an embryo. The receptor variants affect how sensitively your endometrium responds to estrogen signals. If your estrogen receptors aren’t functioning optimally, your endometrial receptivity is compromised, even if your lining looks thick on ultrasound.

Roughly 40% of women carry variants in ESR1 PvuII or XbaI polymorphisms that affect receptor sensitivity and endometrial receptivity. You might have beautiful endometrial thickness. The problem isn’t growth. It’s preparation. Your endometrium isn’t properly primed for implantation. An embryo can be genetically perfect and still fail to implant because the uterine environment isn’t receptive at the genetic level.

You’ve had multiple failed transfers. Your endometrium looks good on ultrasound. You’re eating well, taking supplements, managing stress. But month after month, embryos don’t stick. You’re blamed for implantation failure. The real issue might be that your estrogen receptor variants are making your endometrium less receptive, and standard protocols aren’t accounting for that.

CFTR is famous for cystic fibrosis. But CFTR variants do something else in men: they affect the development of the vas deferens, the tubes that transport sperm from the testes. CFTR carrier variants, particularly loss-of-function mutations, can result in congenital bilateral absence of the vas deferens (CBAVD). The vas deferens simply didn’t develop. There’s nowhere for sperm to go.

CFTR carrier variants occur in roughly 1 in 25 people with European ancestry. Most carriers are perfectly healthy. But in men, even carrier status can increase the risk of congenital absence or obstruction of the vas deferens, leading to obstructive azoospermia, a complete absence of sperm in the ejaculate despite normal sperm production in the testes. Your sperm production is fine. The infrastructure to deliver sperm is broken. Standard semen analysis shows zero sperm, but the problem isn’t testicular failure.

You’re told you have azoospermia and it sounds catastrophic. Your doctor suggests donor sperm or adoption. But if your azoospermia is obstructive due to CBAVD, your sperm is there. It’s just blocked. Sperm retrieval procedures can access it directly from the testes, and your genetic sperm can be used for IVF with ICSI (intracytoplasmic sperm injection).

DAZL is part of the AZF (azoospermia factor) region on the Y chromosome. This gene is essential for spermatogenesis, the process of turning immature cells in the testes into mature sperm. If DAZL is deleted or severely disrupted, sperm production stops. Complete deletion of AZFa or AZFb regions, which include DAZL, means azoospermia: no sperm are produced at all.

Deletions in the DAZL region occur in roughly 1 in 2,000 to 3,000 men with infertility. If you have this deletion, sperm production is severely compromised or completely absent. This isn’t a case where better lifestyle or supplements can help. The genetic machinery for making sperm is missing. Standard testosterone replacement or other hormonal treatments won’t create sperm if the genetic instructions are gone. Azoospermia from AZFa or AZFb deletions is permanent.

You’ve had azoospermia diagnosed. Your testosterone is normal. Your hormone levels look fine. But no amount of lifestyle change will restore sperm production if your DAZL region is deleted. You’re told biological children are impossible. In some cases, depending on where the deletion is and whether some sperm production persists, sperm retrieval may still be possible. But you need genetic testing to know.

The androgen receptor (AR) is how your cells listen to testosterone. It’s not a simple lock-and-key system. The AR gene contains a repeating section of CAG that varies in length from person to person. Longer CAG repeats mean lower androgen receptor sensitivity. Shorter repeats mean higher sensitivity. This variation is common in the population and affects how well your body responds to its own testosterone.

Longer CAG repeat lengths (typically more than 23 repeats) are associated with lower androgen receptor sensitivity, which can impair spermatogenesis and reduce testosterone action throughout the body. You might have normal testosterone levels, but if your androgen receptor isn’t sensitive enough, your cells aren’t fully hearing the testosterone signal. Sperm production slows. Sexual function may be affected. Muscle building and recovery are blunted. You’re functionally less responsive to your own hormone.

Your testosterone levels come back normal. Your doctor says everything looks fine. But you might have oligospermia (low sperm count), poor sperm motility, or reduced sexual function despite adequate testosterone. The problem isn’t your testosterone production. It’s your cells’ ability to respond to testosterone. This is particularly relevant in men considering testosterone replacement therapy; your baseline AR sensitivity predicts how you’ll respond.